Healthcare -
Biotechnology - NASDAQ - US
$ 1.94
-1.52 %
$ 95 M
Market Cap
-1.0
P/E
1. INTRINSIC VALUE
Balance Sheet
Fractyl Health, Inc. Common Stock
| Current Assets | 71.8 M |
| Cash & Short-Term Investments | 67.5 M |
| Receivables | 0 |
| Other Current Assets | 4.3 M |
| Non-Current Assets | 36.3 M |
| Long-Term Investments | 0 |
| PP&E | 31.4 M |
| Other Non-Current Assets | 4.92 M |
| Current Liabilities | 19.8 M |
| Accounts Payable | 3.24 M |
| Short-Term Debt | 4.96 M |
| Other Current Liabilities | 11.6 M |
| Non-Current Liabilities | 59.9 M |
| Long-Term Debt | 57.5 M |
| Other Non-Current Liabilities | 2.33 M |
EFFICIENCY
Earnings Waterfall
Fractyl Health, Inc. Common Stock
| Revenue | 93 K |
| Cost Of Revenue | 50 K |
| Gross Profit | 43 K |
| Operating Expenses | 93.6 M |
| Operating Income | -93.5 M |
| Other Expenses | -24.8 M |
| Net Income | -68.7 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Fractyl Health, Inc. Common Stock
| Net Income | -68.7 M |
| Depreciation & Amortization | 677 K |
| Capital Expenditures | -1.76 M |
| Stock-Based Compensation | 14.4 M |
| Change in Working Capital | 9.59 M |
| Others | -14.6 M |
| Free Cash Flow | -67.3 M |
Wall Street Analysts Price Targets
Fractyl Health, Inc. Common Stock
GUTS has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
GUTS does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Fractyl Health, Inc. Common Stock
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita® Across its Bariatric and Metabolic Endoscopy Centers Nationwide
Collaboration is designed to implement a highly scalable clinical pathway for Revita in post GLP-1 weight maintenance, pending FDA approval, potentially benefiting millions of eligible patients Rising interest from patients and payers for an off-ramp from GLP-1 drugs is fueling significant demand for endoscopic alternatives designed to restore health rather than manage disease BURLINGTON, Mass. and SAN FRANCISCO, June 04, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a metabolic therapeutics company focused on pattern-breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), and Bariendo Inc. (Bariendo), the first all-in-one obesity care platform with cost-effective and durable endoscopic treatments for the rising obesity epidemic, today announced the signing of a non-binding Letter of Intent (the LOI) to explore a future collaboration centered on Fractyl's investigational Revita procedure as a durable off-ramp for weight maintenance following GLP-1 drug discontinuation.
globenewswire.com
- 2 weeks ago
Fractyl Health Advances Rejuva® Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes
First-in-human study will evaluate safety, tolerability, and early efficacy of a one-time, pancreas-targeted smart GLP-1 TM gene therapy for patients with inadequately controlled T2D and obesity
globenewswire.com
- 4 weeks ago
Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025
Data suggests that single dose of RJVA-001 leads to durable metabolic improvements with low systemic GLP-1 exposure in db/db mouse model of T2D— potentially simultaneously addressing durability, adherence, and tolerability challenges seen with current GLP-1 drugs
globenewswire.com
- 1 month ago
Forge Biologics Announces AAV Development and cGMP Manufacturing Relationship with Fractyl Health to Advance Their Gene Therapy Platform for Patients with Metabolic Diseases
COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics (“Forge”), a leading manufacturer of genetic medicines and member of the Ajinomoto Bio-Pharma Services group, today announced an AAV development and manufacturing agreement to help advance Fractyl Health's Rejuva* pancreatic gene therapy platform for the treatment of patients with obesity and type 2 diabetes (T2D). "We developed our FUEL™ platform to provide developers like Fractyl with a more efficient and scalable manufacturing solution to help.
businesswire.com
- 1 month ago
Fractyl Health, Inc. (GUTS) Q1 2025 Earnings Call Transcript
Fractyl Health, Inc. (NASDAQ:GUTS ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Brian Luque - Head of Investor Relations and Corporate Development Harith Rajagopalan - Co Founder and Chief Executive Officer Lisa Davidson - Chief Financial Officer and Treasurer Conference Call Participants Avi Novick - Morgan Stanley Michael DiFiore - Evercore ISI Whitney Ijem - Canaccord Genuity Operator Good afternoon. And welcome to Fractyl Health's First Quarter 2025 Financial Results and Business Updates Call.
seekingalpha.com
- 1 month ago
Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates
REVEAL-1 Cohort 3-month open-label data update expected in June 2025; early clinical signals reinforce Revita's potential to maintain weight loss after GLP-1 discontinuation in the real world REMAIN-1 Midpoint Cohort data expected in Q3 2025; first randomized data on post-GLP-1 weight maintenance REMAIN-1 Pivotal Cohort has completed enrollment ahead of schedule; 6-month primary endpoint data anticipated in H2 2026 Rejuva gene therapy platform advancing toward first-in-human studies; first CTA module submission for RJVA-001 expected in June 2025 Conference call today at 4:30 p.m. ET BURLINGTON, Mass.
globenewswire.com
- 1 month ago
Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference
BURLINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced it will report financial results for the first quarter 2025 and provide business updates on Tuesday, May 13, 2025, at 4:30 p.m.
globenewswire.com
- 1 month ago
Fractyl Health to Present Compelling Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting
BURLINGTON, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (“the Company”), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes of obesity and type 2 diabetes (T2D), today announced that it will deliver an oral presentation of compelling preclinical data from its Rejuva single-administration Smart GLP-1 pancreatic gene therapy platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting, taking place May 13-17, 2025, in New Orleans, Louisiana.
globenewswire.com
- 1 month ago
Fractyl Health Reports Positive Early Data Showing Revita® Has Potential to Prevent Weight Regain After GLP-1 Discontinuation
New REVEAL-1 study results show early signs of weight maintenance after GLP-1 discontinuation REMAIN-1 pivotal study now more than 50% enrolled; midpoint data analysis anticipated in Q3 2025 BURLINGTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (“the Company”), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced positive early data from the open-label REVEAL-1 cohort of its ongoing REMAIN-1 pivotal study.
globenewswire.com
- 2 months ago
Fractyl Health, Inc. (GUTS) Q4 2024 Earnings Call Transcript
Fractyl Health, Inc. (NASDAQ:GUTS ) Q4 2024 Earnings Conference Call March 3, 2025 4:30 PM ET Company Participants Brian Luque – Head of Investor Relations and Corporate Development Harith Rajagopalan – Chief Executive Officer Lisa Davidson – Chief Financial Officer Conference Call Participants Mike Ulz – Morgan Stanley Michael DiFiore – Evercore ISI William Wood – B. Riley Securities Operator Good afternoon, and welcome to Fractyl Health's Fourth Quarter and Full Year 2024 Financial Results and Business Updates Call.
seekingalpha.com
- 3 months ago
Fractyl Health Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates
Strong patient and physician demand for pivotal REMAIN-1 study highlights urgent need for post-GLP-1 withdrawal weight maintenance solutions; midpoint data analysis anticipated in Q2 2025 and full study enrollment expected in summer 2025
globenewswire.com
- 3 months ago
Fractyl Health to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 3, 2025
BURLINGTON, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering pattern breaking approaches for the treatment of obesity and type 2 diabetes (T2D), today announced it will report financial results for the fourth quarter and full year 2024 and provide business updates on Monday, March 3, 2025, at 4:30 p.m.
globenewswire.com
- 3 months ago
8. Profile
Summary
Fractyl Health, Inc. Common Stock GUTS
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 95 M
Dividend Yield
0.00%
Description
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is based in Lexington, Massachusetts.
Contact
17 Hartwell Avenue, Lexington, 02421
https://fractyl.com
IPO
Date
None
Employees
107
Officers
Dr. Timothy J. Kieffer Ph.D.
Chief Scientific Officer
Ms. Sarah S. Toomey Esq.
General Counsel & Corporate Secretary
Ms. Jessica Cotrone
Vice President of Corporate Communications
Mr. Jon Fitzgerald
Senior Vice President of Regulatory, Quality & Clinical
Ms. Lisa A. Davidson MBA
Chief Financial Officer & Treasurer
Mr. Jay D. Caplan BSEE, MBA
Co-Founder, Chief Product Officer & President
Dr. Harith Rajagopalan M.D., Ph.D.
Co-Founder, Chief Executive Officer & Director